19 June 2013
Keywords: idm, expects, l-mtp-pe, ec, decision, 4th, qtr
Article | 14 July 2008
US drugmaker IDM Pharma has requested additional data analyses from a Phase III trial of its osteosarcoma drug mifamurtide in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 July 2008
© 2013 thepharmaletter.com